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Summary In the present multicentre randomized phase 11 trial, the activity and toxicity of three platinum-based combination regimens for the
treatment of advanced non-small-cell lung cancer (NSCLC) were evaluated. The three regimens were: MVP (mitomycin-C 6 mg m-2 on day 1,
vindesine 3 mg m-2 on days 1 and 15, and cisplatin 80 mg m-2 on day 1 every 28 days), PIN (cisplatin 80 mg m-2 day 1, ifosfamide 3 g m-2 day
1 and vinorelbine 25 mg m-2 day 1 and 8 every 21 days) and CaN (carboplatin 350 mg m-2 day 1 and vinorelbine 25 mg m-2 days 1 and 8
every 28 days). A total of 140 chemotherapy-naive patients entered the study; 49 patients were treated with MVP, 48 with PIN and 43 with
CaN. Sixty-seven per cent of the patients had stage IV disease. Response rates, calculated on an 'intention to treat' basis, were as follows:
MVP, 14.3% (95% Cl 5.94-27.2%); PIN, 16.7% (95% Cl 7.4-30.2%); and CaN, 14% (95% Cl 5.3-27.9%). The overall median survivals were
256, 269 and 243 days for patients treated with MVP, PIN and CaN respectively. Myelosuppression was the most frequent toxicity: grade 3-4
leucopenia was observed in 14.3%, 25% and 18.6% of patients treated with MVP, PIN and CaN respectively. This multicentre phase 11
randomized trial shows that MVP, PIN and CaN can be administered on an outpatient basis with acceptable toxicities. Unfortunately, the three
regimens showed an activity significantly lower than that reported in previous single-institution phase 11 trials.
Keywords: platinum-based chemotherapy; advanced non-small-cell lung cancer; randomized phase 11 study
The treatment of advanced non-small-cell lung cancer (NSCLC)
continues to be a challenge to medical oncologists. Several
cytotoxic drugs have been extensively investigated, either alone or
in combination. As single agents, cisplatin (CDDP), ifosfamide
(IFX), mitomycin-C (MMC) and vindesine (VDS) achieve a 5-20%
objective response rate in chemotherapy-naive patients (Sculier,
1984; Johnson, 1990). Recently, vinorelbine (VNR) showed inter-
esting activity in a phase II study and in a large randomized trial
(Depierre et al, 1991; Le Chevalier et al, 1994). Combination
chemotherapy induces a response rate of20-40%, and some authors
have demonstrated that three-drug cisplatin-based regimens are
more active and prolong survival compared with two-drug combina-
tions (Crin6 et al, 1995). However, it is clear that new active combi-
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nations are necessary to improve the prognosis of advanced
NSCLC. Unfortunately, in multicentre randomized trials, many
promising regimens show an anti-tumour activity lower than that
reported in single-institution phase II studies (Ardizzoni et al, 1994;
Ardizzoni, 1996). Therefore, the demonstration of a high response
rate in a phase II trial is insufficient tojustify the implementation of
an expensive large randomized trial.
As a result of these findings, the FONICAP group has started a
series ofconsecutive multicentre randomized phase II trials to eval-
uate the activity ofcombination regimens previously tested in single-
institution phase II studies. The advantage of randomized phase II
trials is the minimization ofselection bias, which is the main cause of
overestimation ofresponse in uncontrolled phase II trials.
In the present study, three regimens were chosen: MVP (mito-
mycin C, vindesine, cisplatin) was chosen because it was consid-
ered to be a reference regimen (Ruckdeschel et al, 1986); PIN
(cisplatin, ifosfamide, vinorelbine) and CaN (carboplatin, vinorel-
bine) had shown interesting activity in phase II trials performed at
single institutions participating with the FONICAP Group (Baldini
et al, 1996; Pronzato et al, 1996).
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PATIENTS AND METHODS
The eligibility criteria were as follows: histologically or cytologi-
cally proven NSCLC, stage IIIB/IV disease; no prior chemo-
therapy; presence ofbidimensionally measurable disease; age < 75
years, World Health Organization (WHO) performance status < 2;
normal haematological (haemoglobin > g dl-', white blood cell
count 4000 ,.l-l and platelet count 100 000 ul-'), renal (creati-
nine clearance > 60 ml min-' and serum creatinine < 1.2 mg dlF')
and liver (total bilirubin < 1.2 mg dl') functions.
The exclusion criteria included the following: active CNS
disorder or brain metastasis, cardiovascular disease (cardiac
failure, myocardial infarction within the previous 3 months,
uncontrolled hypertension or arrhythmias), concomitant neoplasm
other than in situ cervical carcinoma or cutaneous basal cell
cancer. Patients in relapse after surgery were eligible. Patients
previously treated with radiotherapy were eligible ifthey had other
indicator lesions outside the irradiated area.
Pretreatment evaluations included: history and physical exami-
nation, white blood cell count and chemistry profile, electrocardio-
gram (ECG), fibreoptic bronchoscopy, chest radiography, thoracic
computerized tomography scan (CT), abdominal CT scan or ultra-
sound. Bone scan or skeletal radiography and brain CT scan were
performed only when clinically indicated. During treatment, white
blood cell counts, with differential and platelets, were performed
weekly; a physical examination and a chemistry profile were
repeated before day I of each cycle.
Toxicity was evaluated after each cycle of chemotherapy using
standard WHO criteria. A minimum of two cycles of chemo-
therapy were delivered, unless rapid tumour progression was
documented.
Randomization was performed by telephoning the trial office at
the National Institute ofCancer Research in Genoa and the patients
were assigned to receive one of the following regimens: MVP
(MMC 6 mg m- i.v. on day l, VDS 3 mg m-2 i.v. on days 1 and 15,
and CDDP 80 mg m-2 i.v. on day 1), PIN (CDDP 80 mg m-2 i.v. on
day 1, IFX 3 g m-2i.v. on day 1, VNR 25 mg m-2 i.v. on days and
8, Mesna 600 mg m-' i.v. before IFX infusion and 1200 mg m-2
orally 4 and 8 h after IFX) or CaN (CBDCA 350 mg m-2 i.v. on day
I and VNR 25 mg m-2 i.v. on days I and 8). MVP and CaN regi-
mens were repeated every 4 weeks; PIN was repeated every 3
weeks. Chemotherapy was administered on day ifthe white blood
cell count was > 4000gl and platelets 100 000 ul; in the case of
incomplete haematological recovery, chemotherapy was delayed
by I week; in the case of grade 4 (WHO) haematological toxicity,
all the drugs were reduced by 25% in the subsequent courses. In the
event of serum creatinine being greater than 2 mg dl-1 on day 1,
MVP and PIN administration was postponed until normalization,
and a 25% dose reduction ofCDDP and IFX was applied. The dose
ofVNR on day 8 was modified according to the absolute neutrophil
count (ANC) as follows: grade 2 neutropenia, 25% dose reduction;
grade 3 neutropenia, 50% dose reduction; in case of grade 4
neutropenia, VNR was omitted and prophylaxis with oral
ciprofloxacin 1 g d-l and Fluconazole 50 mg d-' was started.
Response to treatment was evaluated after two courses of
chemotherapy: all target lesions were reassessed with the same
technique used at study entry. All responses were checked by a
review committee including the study coordinator and an expert
radiologist, who were not aware of the type of treatment.
Responses were evaluated according to the WHO criteria (Miller
etal, 1981).
Table 1 Patients' characteristics
MVP PIN CaN
Median age (range) (years) 62 (37-69) 64 (45-73) 61 (47-72)
Sex (n)a
Male 41 (83.6) 42 (87.5) 38 (88.3)
Female 8 (16.3) 6 (12.5) 5 (11.6)
Performance status (n)a
0 17 (34.6) 22 (45.8) 20 (46.5)
1 22(44.8) 20 (41.6) 18 (41.8)
2 10 (20.4) 6 (12.5) 5 (11.6)
Histology (n)a
Squamous cell 25 (51.0) 26 (54.1) 21 (48.8)
Adenocarcinoma 20 (40.8) 19 (39.5) 12 (27.9)
Largecell 1 (2.0) 2 (4.1) 3 (6.9)
Unspecified NSCLC 3 (6.1) 1 (2.0) 7 (16.2)
Stage (n)a
Illb 15 (30.6) 18 (37.5) 14 (32.5)
IV 34 (69.3) 30 (62.5) 29 (67.4)
Total number 49 48 43
aNumbers in parentheses are percentages.
Table 2 Toxicities (WHO)
MVP PIN CaN
(n = 45) (n = 44) (n = 39)
G3 G4 G3 G4 G3 G4
Leucopenia (%) 10.2 4.1 16.7 8.3 9.3 9.3
Thrombocytopenia (%) 4.1 2.0 2.1 4.2 7.0 0
Anaemia (%) 6.1 0 10.4 0 2.3 2.3
Nausea and vomiting (%) 8.2 0 12.5 0 2.3 0
Nephrotoxicity (%) 0 0 0 2.1 0 0
Table 3 Responses to treatment
Patients MVP PIN CaN
n(%) n(%) n(%)
All (intention to treat) 7/49 (14.3) 8/48 (16.7) 6/43 (13.9)
Evaluablea 7/40 (17.5) 8/38 (21.0) 6/40 (15.0)
Adequately treatedb 7/34 (20.6) 8/36 (22.2) 6/38 (15.8)
aAll excluding: unelegible, lost to follow-up, never treated, missing data.
bEvaluable excluding: early deaths, toxic deaths.
Patients with complete response (CR), partial response (PR) and
stable disease (SD) were treated for a maximum of six courses;
patients with progressive disease (PD) were withdrawn from treat-
ment and received supportive care. Informed consent was obtained
from all patients according to local institution policies.
Statistical analysis
A centralized randomization was performed by calling the
FONICAP trial office at the National Institute for Cancer Research
in Genoa. Allocation to each treatment arm was made using a
computer-generated list stratified according to the centre.
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Simon's optimal two-stage design for phase II clinical trials was
used to calculate sample size and to minimize the expected number
of patients to be accrued in case of low activity combination
(Simon, 1989). Sample size was calculated on the following
assumptions: alpha error = 0.05, beta error = 0.10; P0 (clinically
uninteresting true response rate) and P1 (sufficiently promising
true response rate), defined according to Simon, were set at 10%
and 30% respectively. In the first stage, 18 patients in each arm had
to be randomized: if two or less responses were observed, the
accrual had to be stopped; otherwise, 17 more patients had to be
accrued. The drug combination was considered ofinterest if seven
or more responses were observed out of 35 evaluable patients.
Because of the study design, a formal comparison of the three
regimens was not planned.
All randomized patients were included in the final analysis of
response on an 'intention to treat' basis; early deaths and early
progressions were considered treatment failures.
Duration of response and survival were calculated from date of
randomization; overall survival curves were plotted using the
Kaplan-Meier method (Kaplan, 1958).
RESULTS
Patient population
From August 1993 to October 1994, 140 advanced NSCLC
patients entered the study. In the first step, all three regimens
achieved the minimum number ofresponses required to proceed to
the second stage. Therefore, 49 patients were randomized to
receive MVP, 48 PIN and 43 CaN. The majority of the patients
were men in good general conditions ofhealth and who had stage
IV disease. Patients characteristics were very similar in the three
study groups (Table 1). Out of a total of 140 randomized patients
three were not eligible: two patients in the MVP arm (one SCLC
and one stage IIIB because oftracheal invasion) and one patient in
the PIN arm (brain metastasis).
Toxicity
Treatment toxicity was evaluable in 128 patients. Table 2 summa-
rizes the worst toxicities per patient. Twenty patients required dose
and schedule modifications because of toxicity (nine MVP, six
PIN and five CaN). The main side-effect was myelosuppression:
grade 3-4 leucopenia was observed in 14.3%, 25% and 18.6% of
patients treated with MVP, PIN and CaN respectively. Severe
nausea and vomiting were more frequently observed in patients
receiving the PIN regimen. One patient receiving the PIN
chemotherapy experienced a grade 4 nephrotoxicity. No severe
neurotoxicity was observed. Three toxic deaths were reported: two
patients receiving CaN chemotherapy died because ofneutropenic
fever and sepsis, and one patient being treated with PIN died
because of adynamic ileus.
Activity and efficacy
Nineteen patients (MVP seven, PIN nine, CaN three) were not
evaluable for response: seven patients were not evaluable because
of inadequate follow-up (mostly lack of confirmation of response
at 4 weeks), six because of inadequate response documentation,
and six patients refused treatment. Seven early deaths (patients
died before response evaluation) were reported: six patients
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Figure 1 Overall survival curves
receiving MVP and one patient receiving PIN (this patient died
because of toxicity). All these patients were recorded as 'non-
responders' in the intention to treat analysis. The overall response
rates, reviewed by the committee, were as follows (Table 3): MVP,
7 of 49 (14.3%, 95% CI 5.94-27.2%); PIN, 8 of 48 (16.7%, 95%
CI 7.4-30.2%); and CaN, 6 of 43 (14%, 95% CI 5.3-27.9%). No
complete responses were observed. All randomized patients were
included in survival analyses: the median overall survivals were
8.4, 8.8 and 7.9 months for patients treated with MVP, PIN and
CaN respectively. At I year, nine patients treated with MVP were
alive; seven patient treated with PIN and seven with CaN were
also alive (Figure 1).
DISCUSSION
Chemotherapy has been found to slightly improve the survival of
patients with advanced NSCLC and, so far, cisplatin-containing regi-
mens have been considered the gold standard (Stewart et al, 1995).
The PIN regimen is a new three-drug combination including
cisplatin, vinorelbine and ifosfamide; ifosfamide was chosen
because of its activity as a single agent and its synergism with
cisplatin in experimental models (Goldin, 1982). This regimen had
shown a 60% overall response rate in a prior single-institution
phase II study (Baldini et al, 1994); this high level of anti-tumour
activity has been recently confirmed, by the same group, on a
larger series ofpatients (Baldini et al, 1996).
Carboplatin is a platinum analogue with non-haematological
toxicity more favourable than that ofthe parent compound: for this
reason, many phase II studies have been performed using carbo-
platin alone or in combination. The activity of the combination
carboplatin/vinorelbine was tested in NSCLC patients with a
response rate ranging from 28% to 36% in different studies, and
the toxicity of the combination was generally reported as being
mild (Santomaggio et al, 1994; Pronzato et al, 1996).
In this study, all three regimens, MVP, PIN and CaN, were
feasible on an outpatient basis, however their level ofactivity was
below 30%, which was the value that had been assigned as cut-off
tojustify further phase III comparisons. The discrepancy between
these data and those previously published might be because of
several reasons: in the present randomized trial the proportion of
stage IV patients was higher than those enrolled into uncontrolled
phase II studies; furthermore, anti-tumour activity was calculated
using an 'intention to treat' analysis, in which unevaluable patients
were also included in the denominator; finally, the central review
of radiological material led to the cancellation of a number of
responses as judged by the investigators. Another large trial has
previously reported response rates similar to those that we have
observed with the MVP regimen (Einhorn et al, 1986).
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In conclusion, in the present study, none of the chemotherapy
combinations reached the level of activity considered to be of
interest to initiate a randomized phase III trial. Randomized phase
II studies are a reliable and rapid method to screen the anti-tumour
activity ofnew agents or combinations and can be used to plan the
design ofphase III randomized trials.
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